AltPep
- Founded: 2018
- Location: Seattle, WA
- Employee range: 11 - 50
- Clinical stage: Clin0
- Therapy area: Alzheimer's
- Drug types: NEU
- Lead product: Sobin Therapeutics
- Product link: https://www.altpep.com/product-pipeline/
- Funding: $53M B Jun 2023
- Investors: Senator Investment Group, Section 32, Partners Investment, Eli Lilly and Company, Alexandria Venture Investments, Matrix Capital Management Company
altpep.com linkedin.com job board
Short description:
Alternating Peptides for Neurological Diseases
Drug notes:
Also RD/Clin0 Parkinson's; Soba diagnostics in development for Alzheimer's & Parkinson's
Long description:
AltPep is developing treatments and detection tools for amyloid diseases. Unfolded or misfolded proteins can accumulate into harmful deposits that have been linked with neurodegenerative and systemic disorders called amyloid diseases. AltPep identified a novel protein structure, alpha-sheet, using computer modeling techniques that is thought to be causal to misfolded aggregates in over 50 amyloid diseases. Using this knowledge, AltPep has created a platform of de novo synthetic peptides designed to target and neutralize the impact of these misfolded aggregates at the early stages of disease. In addition, AltPep is using the presence of these aggregates to create their SOBA Diagnostic platform that is being investigated for use in Alzheimer’s and Parkinson’s diseases.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com